References
- Patel NA, Patel NJ, Patel RP. Design and evaluation of transdermal drug delivery system for curcumin as an anti-inflammatory drug. Drug Dev Ind Pharm 2009;35:234–42
- Appiah-Opong R, Commandeur JNM, van Vugt-Lussenburg B, et al. Inhibition of human recombinant cytochrome P450s by curcumin and curcumin decomposition products. Toxicology 2007;235:83–91
- Aggarwal S, Ichikawa H, Takada Y, et al. Curcumin (diferuloylmethane) down-regulates expression of cell proliferation and antiapoptotic and metastatic gene products through suppression of IκBα kinase and Akt activation. Mol Pharmacol 2006;69:195–206
- Mach CM, Chen JH, Mosley SA, et al. Evaluation of liposomal curcumin cytochrome p450 metabolism. Anticancer Res 2010;30:811–14
- Si D, Wang Y, Zhou Y-H, et al. Mechanism of CYP2C9 inhibition by flavones and flavonols. Drug Metab Dispos 2009;37:629–34
- Miners JO, Birkett DJ. Cytochrome P4502C9: an enzyme of major importance in human drug metabolism. Br J Clin Pharmacol 1998;45:525–38
- Emoto C, Murase S, Iwasaki K. Approach to the prediction of the contribution of major cytochrome P450 enzymes to drug metabolism in the early drug-discovery stage. Xenobiotica 2006;36:671–83
- Zhou S, Zhou Z, Yang L, et al. Substrates, inducers, inhibitors and structure–activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem 2009;16:3480–675
- Suvarna R, Pirmohamed M, Henderson L. Possible interaction between warfarin and cranberry juice. BMJ 2003;327:1454
- Thapliyal R, Maru G. Inhibition of cytochrome P450 isozymes by curcumins in vitro and in vivo. Food Chem Toxicol 2001;39:541–7
- Lee DY, Lee SJ, Lee MG. Effects of enzyme inducers and inhibitors on the pharmacokinetics of intravenous torasemide in rats. Int J Pharm 2005;298:38–46
- Wang X, Lee W, Or P, et al. Pharmacokinetic interaction studies of tanshinones with tolbutamide, a model CYP2C11 probe substrate, using liver microsomes, primary hepatocytes and in vivo in the rat. Phytomedicine 2010;17:203–11
- Grillo MP, Ma J, Teffera Y, et al. A novel bioactivation pathway for diclofenac initiated by P450 mediated oxidative decarboxylation. Drug Metab Dispos 2008;36:1740–4
- Yan Z, Li J, Huebert N, et al. Detection of a novel reactive metabolite of diclofenac: evidence for CYP2C9-mediated bioactivation via arene oxides. Drug Metab Dispos 2005;33:706–13
- Shi R, Wang Y, Zhu X, et al. Exploration of the binding of curcumin analogues to human P450 2C9 based on docking and molecular dynamics simulation. J Mol Model 2012;18:2599–611
- Wang H, Cheng JD, Montgomery D, et al. Evaluation of the binding orientations of testosterone in the active site of homology models for CYP2C11 and CYP2C13. Biochem Pharmacol 2009;78:406–13
- Cho Y, Lee W, Choi J. Effects of curcumin on the pharmacokinetics of tamoxifen and its active metabolite, 4-hydroxytamoxifen, in rats: possible role of CYP3A4 and P-glycoprotein inhibition by curcumin. Pharmazie 2012;67:124–30
- Rettie AE, Jones JP. Clinical and toxicological relevance of CYP2C9: drug–drug interactions and pharmacogenetics. Annu Rev Pharmacol Toxicol 2005;45:477–94
- Masubuchi Y, Ose A, Horie T. Mechanism-based inactivation of CYP2C11 by diclofenac. Drug Metab Dispos 2001;29:1190–5
- Sharma RA, Euden SA, Platton SL, et al. Phase I clinical trial of oral curcumin biomarkers of systemic activity and compliance. Clin Can Res 2004;10:6847–54
- Wu X, Xu J, Huang X, et al. Self-microemulsifying drug delivery system improves curcumin dissolution and bioavailability. Drug Dev Ind Pharm 2011;37:15–23